CLINICAL EVIDENCE
REGENPRP™-HA COMBINATION FOR KNEE OA: ZHANG 2025
MRI analysis demonstrated a significant reduction in bone marrow edema at 12 months with the RegenPRP™-HA combination prepared using Cellular Matrix.
Significant reduction in bone marrow edema versus HA alone at 12 months (p=0.030).
A randomized, double-blind controlled trial compared the clinical efficacy and structural MRI outcomes of the RegenPRP™-HA combination prepared with Cellular Matrix versus hyaluronic acid (HA) alone in patients with knee osteoarthritis. Participants received two intra-articular injections administered 2-4 weeks apart and were followed for 12 months.
- Number of patients: 58 (29 HA+PRP, 29 HA)
- Mean age: 57 years
- Kellgren-Lawrence grade II-III knee osteoarthritis
- Follow-up: 12 months
- MRI evaluation using Whole-Organ MRI Score (WORMS) methodology
RESULTS
- Both the RegenPRP™-HA and HA groups demonstrated improvements in pain and function over 12 months.
- No significant between-group differences were observed for VAS pain scores, WOMAC scores, EQ-5D-5L, or total WORMS score at 12 months.
- MRI assessment showed a significant reduction in bone marrow edema in the RegenPRP™-HA group compared with HA alone at 12 months (−0.7 vs +0.7; p=0.030).
- The addition of PRP was associated with structural improvements detected on MRI despite similar clinical outcomes between treatment groups.
CONCLUSION
Both RegenPRP™-HA and HA alone improved pain and function in patients with grade II-III knee osteoarthritis over 12 months. While clinical superiority was not demonstrated, the RegenPRP™-HA combination prepared with Cellular Matrix was associated with a significant reduction in bone marrow edema on MRI, suggesting potential structural benefits.